Trial Outcomes & Findings for Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas (NCT NCT03786926)

Last Updated: 2025-06-26

Results Overview

A DLT was defined as the occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless equivocally due to underlying malignancy or an extraneous cause. AEs were graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0: non-hematologic toxicity: all non-hematologic TEAEs of grade 3 or greater with the exception of grade 3 nausea or vomiting that could be controlled by supportive therapy; hematologic toxicity: grade 4 neutropenia \>5 days, grade 4 thrombocytopenia or grade 3 thrombocytopenia with bleeding event or requiring platelet transfusion, grade \>=3 febrile neutropenia (defined as absolute neutrophil count \[ANC\] \<1000/cubic millimeter {mm\^3} with a single temperature \>38.3 degree Celsius \[°C\] or a sustained temperature of \>=38°C for more than 1 hour), grade 4 anemia not explained by underlying disease; any TEAE that required a dose delay of \>=15 days; any case of Hy's Law.

Recruitment status

TERMINATED

Study phase

PHASE1

Target enrollment

53 participants

Primary outcome timeframe

From the first dose of study drug (Day 1) up to Day 28 of Cycle 1 (each cycle is 28 days)

Results posted on

2025-06-26

Participant Flow

This Phase 1, 2-part, open-label study was conducted in patients with relapsed, refractory, or resistant lymphoma.

The study consisted of a dose escalation stage (stage 1) and a dose expansion stage (stage 2). A total of 23 patients in dose escalation stage and 30 patients in dose expansion stage were enrolled in this study. The study was terminated based on strategic evaluation of the clinical development of HMPL-689 in the United States, Europe, and Australia with no safety concerns.

Participant milestones

Participant milestones
Measure	Dose Escalation Stage: HMPL-689 5 mg QD Patients received HMPL-689 5 milligram (mg) once daily (QD) orally for continuous 28-day treatment cycles until disease progression (PD), death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) received HMPL-689 at recommended phase 2 dose (RP2D), that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with follicular lymphoma (FL) received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with marginal zone lymphoma (MZL) received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with mantle cell lymphoma (MCL) received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Overall Study STARTED	3	3	5	3	6	3	3	13	6	3	5
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	3	3	5	3	6	3	3	13	6	3	5

Reasons for withdrawal

Reasons for withdrawal
Measure	Dose Escalation Stage: HMPL-689 5 mg QD Patients received HMPL-689 5 milligram (mg) once daily (QD) orally for continuous 28-day treatment cycles until disease progression (PD), death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) received HMPL-689 at recommended phase 2 dose (RP2D), that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with follicular lymphoma (FL) received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with marginal zone lymphoma (MZL) received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with mantle cell lymphoma (MCL) received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Overall Study Adverse Event	0	0	0	0	0	0	0	1	1	0	1
Overall Study Progressive disease	3	0	3	1	2	2	1	6	1	1	1
Overall Study Death	0	1	1	0	0	0	0	0	0	1	2
Overall Study Physician Decision	0	1	0	1	2	0	0	2	1	1	0
Overall Study Withdrawal by Subject	0	1	1	0	0	0	1	0	1	0	1
Overall Study Study terminated by Sponsor	0	0	0	0	1	0	0	4	0	0	0
Overall Study Anti-neoplasm treatment	0	0	0	0	1	0	1	0	0	0	0
Overall Study Other	0	0	0	1	0	1	0	0	2	0	0

Baseline Characteristics

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=3 Participants Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL n=13 Participants Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL n=6 Participants Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM n=3 Participants Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL n=5 Participants Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Total n=53 Participants Total of all reporting groups
Age, Continuous	69.7 years STANDARD_DEVIATION 6.51 • n=5 Participants	70.7 years STANDARD_DEVIATION 13.05 • n=7 Participants	64.8 years STANDARD_DEVIATION 17.18 • n=5 Participants	67.7 years STANDARD_DEVIATION 3.51 • n=4 Participants	63.8 years STANDARD_DEVIATION 7.68 • n=21 Participants	59.0 years STANDARD_DEVIATION 17.69 • n=8 Participants	65.7 years STANDARD_DEVIATION 5.03 • n=8 Participants	61.7 years STANDARD_DEVIATION 10.16 • n=24 Participants	72.3 years STANDARD_DEVIATION 9.56 • n=42 Participants	63.7 years STANDARD_DEVIATION 4.16 • n=42 Participants	75.8 years STANDARD_DEVIATION 8.23 • n=42 Participants	66.2 years STANDARD_DEVIATION 10.63 • n=42 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	9 Participants n=24 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	21 Participants n=42 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	1 Participants n=7 Participants	5 Participants n=5 Participants	3 Participants n=4 Participants	3 Participants n=21 Participants	2 Participants n=8 Participants	1 Participants n=8 Participants	4 Participants n=24 Participants	5 Participants n=42 Participants	2 Participants n=42 Participants	4 Participants n=42 Participants	32 Participants n=42 Participants
Race/Ethnicity, Customized White	3 Participants n=5 Participants	3 Participants n=7 Participants	5 Participants n=5 Participants	3 Participants n=4 Participants	5 Participants n=21 Participants	3 Participants n=8 Participants	3 Participants n=8 Participants	13 Participants n=24 Participants	6 Participants n=42 Participants	3 Participants n=42 Participants	5 Participants n=42 Participants	52 Participants n=42 Participants
Race/Ethnicity, Customized Other	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants
Race/Ethnicity, Customized Hispanic or Latino	0 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	3 Participants n=24 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	9 Participants n=42 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	3 Participants n=5 Participants	1 Participants n=7 Participants	5 Participants n=5 Participants	3 Participants n=4 Participants	5 Participants n=21 Participants	3 Participants n=8 Participants	3 Participants n=8 Participants	10 Participants n=24 Participants	4 Participants n=42 Participants	3 Participants n=42 Participants	3 Participants n=42 Participants	43 Participants n=42 Participants
Race/Ethnicity, Customized Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants

PRIMARY outcome

Timeframe: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1 (each cycle is 28 days)

Population: The DLT evaluable analysis set (DEAS) was defined as all patients enrolled in the dose escalation stage of the study who were evaluable for DLT assessment. A patient was DLT evaluable if: had received at least 75% of the assigned dose of study drug during the DLT assessment window or had not completed the DLT assessment period due to a DLT.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months

Population: The FAS included all patients who received at least 1 dose of HMPL-689.

An AE was any untoward medical occurrence in a clinical investigation patient administered a study drug, regardless of causal attribution. An SAE was an AE that resulted in any of the following: was fatal, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect in a neonate/infant born to a female patient or female partner of a male patient exposed to the study drug, or was considered a significant medical event by the investigator. TEAEs were defined as AEs with onset date on or after the first dose of study drug and no later than 30 days after the date of last study drug administration or start of a new study drug of anti-neoplasm therapy, whichever was earlier. Treatment related AEs and SAEs were defined as AEs and SAEs collected later than 30 days after the last study drug date or start of a new study drug of anti-neoplasm therapy.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment Related Treatment-Emergent Adverse Events (TRAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment Related Serious Adverse Events (TRSAEs) Any TEAE	3 Participants	3 Participants	5 Participants	3 Participants	6 Participants	3 Participants	—	—	—	—	—
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment Related Treatment-Emergent Adverse Events (TRAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment Related Serious Adverse Events (TRSAEs) Any TRAE	1 Participants	3 Participants	4 Participants	3 Participants	6 Participants	3 Participants	—	—	—	—	—
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment Related Treatment-Emergent Adverse Events (TRAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment Related Serious Adverse Events (TRSAEs) Any TESAE	0 Participants	2 Participants	2 Participants	3 Participants	2 Participants	1 Participants	—	—	—	—	—
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment Related Treatment-Emergent Adverse Events (TRAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment Related Serious Adverse Events (TRSAEs) Any TRSAE	0 Participants	0 Participants	1 Participants	2 Participants	2 Participants	0 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 27 months

Population: The FAS included all patients who received at least 1 dose of HMPL-689.

An AE was any untoward medical occurrence in a clinical investigation patient administered a study drug, regardless of causal attribution. TEAEs were defined as AEs with onset date on or after the first dose of study drug and no later than 30 days after the date of last study drug administration or start of a new study drug of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were defined as AEs collected later than 30 days after the last study drug date or start of a new study drug of anti-neoplasm therapy.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=13 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=6 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=5 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Expansion Stage: Number of Patients With Treatment-Emergent Adverse Events and Treatment Related Treatment-Emergent Adverse Events Any TRAE	3 Participants	12 Participants	5 Participants	2 Participants	4 Participants	—	—	—	—	—	—
Dose Expansion Stage: Number of Patients With Treatment-Emergent Adverse Events and Treatment Related Treatment-Emergent Adverse Events Any TEAE	3 Participants	13 Participants	5 Participants	3 Participants	5 Participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7days) thereafter, up to a maximum of 58 months

Population: The efficacy analysis set (EAS) included all patients who received at least 1 dose of HMPL-689 and had a baseline tumor assessment and at least 1 evaluable post-baseline assessment unless death occurred before the first post-baseline assessment.

ORR: percentage of patients with complete response (CR),CR with incomplete marrow recovery (CRi),nodular partial response (nPR),PR with lymphocytosis (PR-L) or PR for CLL patients; CR, very good PR (VGPR),PR or minor response (MR) for WM patients;CR or PR for patients with disease other than CLL and WM.CR: absence of serum (S) monoclonal immunoglobulin (Ig)M, normal S IgM, complete resolution of extramedullary disease,morphologically normal bone marrow aspirate and trephine biopsy. CRi:criteria fulfilled for CR but persistent cytopenia,anemia,thrombocytopenia or neutropenia. nPR:patients with residual CLL cells.PR-L:patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy.PR, VGPR, MR: detectable monoclonal IgM,no new signs/symptoms of active disease and PR: ≥50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM,complete resolution of extramedullary disease,MR: \>=25% but \<50% reduction in S IgM.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=2 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=5 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=3 Participants Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL n=13 Participants Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL n=6 Participants Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM n=2 Participants Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL n=4 Participants Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation and Dose Expansion Stages: Objective Response Rate (ORR)	33.3 percentage of patients Interval 0.8 to 90.6	66.7 percentage of patients Interval 9.4 to 99.2	80.0 percentage of patients Interval 28.4 to 99.5	100.0 percentage of patients Interval 15.8 to 100.0	60.0 percentage of patients Interval 14.7 to 94.7	66.7 percentage of patients Interval 9.4 to 99.2	66.7 percentage of patients Interval 9.4 to 99.2	84.6 percentage of patients Interval 54.6 to 98.1	50.0 percentage of patients Interval 11.8 to 88.2	100.0 percentage of patients Interval 15.8 to 100.0	100.0 percentage of patients Interval 39.8 to 100.0

SECONDARY outcome

Timeframe: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7days) thereafter, up to a maximum of 58 months

Population: The EAS included all patients who received at least 1 dose of HMPL-689 and had a baseline tumor assessment and at least 1 evaluable post-baseline assessment unless death occurred before the first post-baseline assessment. Only patients with CR, CRi, PR, nPR, VGPR, PR-L, or MR were included in the analysis.

TTR was defined as the time from the first dose of study drug to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. PR: detectable monoclonal IgM, no new signs/symptoms of active disease, 50% but \<90% reduction in serum IgM, reduction in extramedullary disease. nPR: patients with residual CLL cells. VGPR: detectable monoclonal IgM, no new signs/symptoms of active disease,\>=90% reduction in serum IgM, complete resolution of extramedullary disease. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. MR: detectable monoclonal IgM, no new signs/symptoms of active disease, \>=25% but \<50% reduction in serum IgM.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=1 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=2 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=4 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=2 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=3 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=2 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=2 Participants Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL n=11 Participants Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL n=3 Participants Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM n=2 Participants Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL n=4 Participants Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation and Dose Expansion Stages: Time to Response (TTR)	1.87 months Interval 1.87 to 1.87	1.72 months Interval 1.68 to 1.77	8.80 months Interval 1.91 to 19.55	1.77 months Interval 1.68 to 1.87	2.27 months Interval 1.87 to 11.14	1.84 months Interval 1.84 to 1.84	2.81 months Interval 1.87 to 3.75	1.74 months Interval 1.64 to 2.07	2.53 months Interval 1.91 to 2.79	3.73 months Interval 1.84 to 5.62	1.76 months Interval 1.71 to 1.84

SECONDARY outcome

Timeframe: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7days) thereafter, up to a maximum of 58 months

DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L and MR) was achieved until earlier of first documentation of definitive PD or death from any cause, whichever was earlier. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: ≥50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to the disease.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=1 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=2 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=4 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=2 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=3 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=2 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=2 Participants Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL n=11 Participants Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL n=3 Participants Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM n=2 Participants Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL n=4 Participants Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation and Dose Expansion Stages: Duration of Response (DOR)	1.9 months NA indicates that upper and lower limits of confidence interval (CI) were not estimable due to insufficient number of patients with events at study closure.	31.9 months NA indicates that upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.	13.7 months Interval 12.6 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	NA months Interval 9.3 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	NA months NA indicates that median, upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.	NA months Interval 1.9 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	NA months Interval 4.6 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	NA months Interval 1.9 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	NA months NA indicates that median, upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.	NA months Interval 4.9 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	9.1 months Interval 3.7 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.

SECONDARY outcome

Timeframe: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter, up to a maximum of 58 months

CBR was defined as percentage of patients who had best overall response (BOR) with stable disease (SD) or better. BOR was defined as the best response recorded from the start of treatment until PD or new anti-cancer therapy, whichever came earlier. PD: \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease. SD: detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=2 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=5 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=3 Participants Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL n=13 Participants Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL n=6 Participants Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM n=2 Participants Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL n=4 Participants Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation and Dose Expansion Stages: Clinical Benefit Rate (CBR)	100.0 percentage of patients Interval 29.2 to 100.0	100.0 percentage of patients Interval 29.2 to 100.0	80.0 percentage of patients Interval 28.4 to 99.5	100.0 percentage of patients Interval 15.8 to 100.0	80.0 percentage of patients Interval 28.4 to 99.5	66.7 percentage of patients Interval 9.4 to 99.2	100.0 percentage of patients Interval 29.2 to 100.0	84.6 percentage of patients Interval 54.6 to 98.1	83.3 percentage of patients Interval 35.9 to 99.6	100.0 percentage of patients Interval 15.8 to 100.0	100.0 percentage of patients Interval 39.8 to 100.0

SECONDARY outcome

Timeframe: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter, up to a maximum of 58 months

Population: The FAS included all patients who received at least 1 dose of HMPL-689.

PFS was defined as the time from the date of first study drug to the earliest date of PD or death of any cause, whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=3 Participants Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL n=13 Participants Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL n=6 Participants Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM n=3 Participants Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL n=5 Participants Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation and Dose Expansion Stages: Progression-Free Survival (PFS)	5.3 months Interval 3.8 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	33.6 months NA indicates that upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.	16.6 months Interval 1.9 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	NA months Interval 11.0 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	13.6 months Interval 1.8 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	3.7 months Interval 1.7 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	NA months Interval 8.3 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	11.9 months Interval 1.8 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	5.6 months Interval 2.1 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	NA months Interval 10.4 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	10.8 months Interval 5.5 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.

SECONDARY outcome

Timeframe: Pre-dose on Days 1, 2, 15, 16, 28 of Cycle 1 and on Day 1 of Cycle 2; 0.5, 1, 2, 4 and 8 hours post-dose on Days 1, 15 and 28 of Cycle 1 (each cycle is 28 days)

Population: The pharmacokinetic analysis set (PKAS) included all patients who received at least 1 dose of HMPL-689 and had at least 1 PK sample obtained and analyzed. Only patients with data collected at specified timepoints are reported.

Blood samples were collected to determine plasma concentration of HMPL-689. The pharmacokinetic (PK) parameters were determined by non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 1	0.000 nanograms per milliliter (ng/mL) Standard Deviation 0.000	0.000 nanograms per milliliter (ng/mL) Standard Deviation 0.000	0.000 nanograms per milliliter (ng/mL) Standard Deviation 0.000	0.000 nanograms per milliliter (ng/mL) Standard Deviation 0.000	0.000 nanograms per milliliter (ng/mL) Standard Deviation 0.000	0.000 nanograms per milliliter (ng/mL) Standard Deviation 0.000	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 0.5 hour post-dose: Day 1 Cycle 1	1.153 nanograms per milliliter (ng/mL) Standard Deviation 1.220	65.133 nanograms per milliliter (ng/mL) Standard Deviation 72.976	19.322 nanograms per milliliter (ng/mL) Standard Deviation 18.574	87.733 nanograms per milliliter (ng/mL) Standard Deviation 68.441	47.424 nanograms per milliliter (ng/mL) Standard Deviation 78.327	36.907 nanograms per milliliter (ng/mL) Standard Deviation 32.999	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 1 hour post-dose: Day 1 Cycle 1	14.457 nanograms per milliliter (ng/mL) Standard Deviation 14.965	71.346 nanograms per milliliter (ng/mL) Standard Deviation 63.493	66.740 nanograms per milliliter (ng/mL) Standard Deviation 41.460	125.100 nanograms per milliliter (ng/mL) Standard Deviation 78.083	110.780 nanograms per milliliter (ng/mL) Standard Deviation 70.347	184.000 nanograms per milliliter (ng/mL) Standard Deviation 176.952	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 2 hours post-dose: Day 1 Cycle 1	22.200 nanograms per milliliter (ng/mL) Standard Deviation 4.629	50.887 nanograms per milliliter (ng/mL) Standard Deviation 41.833	98.260 nanograms per milliliter (ng/mL) Standard Deviation 16.955	108.067 nanograms per milliliter (ng/mL) Standard Deviation 27.749	141.600 nanograms per milliliter (ng/mL) Standard Deviation 82.032	167.033 nanograms per milliliter (ng/mL) Standard Deviation 75.883	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 4 hours post-dose: Day 1 Cycle 1	19.267 nanograms per milliliter (ng/mL) Standard Deviation 4.186	44.467 nanograms per milliliter (ng/mL) Standard Deviation 22.299	95.260 nanograms per milliliter (ng/mL) Standard Deviation 33.323	67.367 nanograms per milliliter (ng/mL) Standard Deviation 30.596	103.700 nanograms per milliliter (ng/mL) Standard Deviation 33.787	111.533 nanograms per milliliter (ng/mL) Standard Deviation 49.843	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 8 hours post-dose: Day 1 Cycle 1	15.100 nanograms per milliliter (ng/mL) Standard Deviation 4.190	35.867 nanograms per milliliter (ng/mL) Standard Deviation 9.063	48.440 nanograms per milliliter (ng/mL) Standard Deviation 18.373	36.700 nanograms per milliliter (ng/mL) Standard Deviation 13.981	68.120 nanograms per milliliter (ng/mL) Standard Deviation 27.164	72.600 nanograms per milliliter (ng/mL) Standard Deviation 19.128	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 2 Cycle 1	4.490 nanograms per milliliter (ng/mL) Standard Deviation 1.360	11.527 nanograms per milliliter (ng/mL) Standard Deviation 6.411	12.442 nanograms per milliliter (ng/mL) Standard Deviation 5.112	8.887 nanograms per milliliter (ng/mL) Standard Deviation 4.148	20.017 nanograms per milliliter (ng/mL) Standard Deviation 8.614	13.433 nanograms per milliliter (ng/mL) Standard Deviation 1.501	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 15 Cycle 1	4.580 nanograms per milliliter (ng/mL) Standard Deviation 0.521	35.613 nanograms per milliliter (ng/mL) Standard Deviation 39.872	12.450 nanograms per milliliter (ng/mL) Standard Deviation 9.931	11.100 nanograms per milliliter (ng/mL) Standard Deviation 10.026	29.250 nanograms per milliliter (ng/mL) Standard Deviation 14.562	22.900 nanograms per milliliter (ng/mL) Standard Deviation 11.077	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 0.5 hour post-dose: Day 15 Cycle 1	5.443 nanograms per milliliter (ng/mL) Standard Deviation 2.145	118.433 nanograms per milliliter (ng/mL) Standard Deviation 82.709	44.295 nanograms per milliliter (ng/mL) Standard Deviation 40.717	59.667 nanograms per milliliter (ng/mL) Standard Deviation 52.905	45.180 nanograms per milliliter (ng/mL) Standard Deviation 29.456	21.733 nanograms per milliliter (ng/mL) Standard Deviation 9.166	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 1 hour post-dose: Day 15 Cycle 1	19.300 nanograms per milliliter (ng/mL) Standard Deviation 26.414	115.400 nanograms per milliliter (ng/mL) Standard Deviation 69.730	66.900 nanograms per milliliter (ng/mL) Standard Deviation 50.101	100.667 nanograms per milliliter (ng/mL) Standard Deviation 63.801	94.420 nanograms per milliliter (ng/mL) Standard Deviation 72.734	116.667 nanograms per milliliter (ng/mL) Standard Deviation 16.773	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 2 hours post-dose: Day 15 Cycle 1	31.123 nanograms per milliliter (ng/mL) Standard Deviation 24.388	79.867 nanograms per milliliter (ng/mL) Standard Deviation 23.500	86.425 nanograms per milliliter (ng/mL) Standard Deviation 42.718	102.900 nanograms per milliliter (ng/mL) Standard Deviation 22.999	122.220 nanograms per milliliter (ng/mL) Standard Deviation 86.832	187.333 nanograms per milliliter (ng/mL) Standard Deviation 88.636	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 4 hours post-dose: Day 15 Cycle 1	20.323 nanograms per milliliter (ng/mL) Standard Deviation 11.020	56.200 nanograms per milliliter (ng/mL) Standard Deviation 22.311	91.625 nanograms per milliliter (ng/mL) Standard Deviation 31.814	97.667 nanograms per milliliter (ng/mL) Standard Deviation 14.468	153.400 nanograms per milliliter (ng/mL) Standard Deviation 30.345	158.833 nanograms per milliliter (ng/mL) Standard Deviation 63.135	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 8 hours post-dose: Day 15 Cycle 1	15.933 nanograms per milliliter (ng/mL) Standard Deviation 2.307	37.533 nanograms per milliliter (ng/mL) Standard Deviation 16.861	73.233 nanograms per milliliter (ng/mL) Standard Deviation 14.758	58.450 nanograms per milliliter (ng/mL) Standard Deviation 9.122	87.620 nanograms per milliliter (ng/mL) Standard Deviation 26.685	77.367 nanograms per milliliter (ng/mL) Standard Deviation 25.143	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 16 Cycle 1	5.567 nanograms per milliliter (ng/mL) Standard Deviation 0.958	61.367 nanograms per milliliter (ng/mL) Standard Deviation 87.227	17.825 nanograms per milliliter (ng/mL) Standard Deviation 4.234	15.100 nanograms per milliliter (ng/mL) Standard Deviation 1.556	31.320 nanograms per milliliter (ng/mL) Standard Deviation 13.989	20.267 nanograms per milliliter (ng/mL) Standard Deviation 9.393	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 28 Cycle 1	5.837 nanograms per milliliter (ng/mL) Standard Deviation 1.257	10.885 nanograms per milliliter (ng/mL) Standard Deviation 1.860	19.575 nanograms per milliliter (ng/mL) Standard Deviation 9.215	25.133 nanograms per milliliter (ng/mL) Standard Deviation 7.251	32.380 nanograms per milliliter (ng/mL) Standard Deviation 17.181	21.200 nanograms per milliliter (ng/mL) Standard Deviation 10.121	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 0.5 hour post-dose: Day 28 Cycle 1	17.383 nanograms per milliliter (ng/mL) Standard Deviation 22.271	101.100 nanograms per milliliter (ng/mL) Standard Deviation 56.427	39.950 nanograms per milliliter (ng/mL) Standard Deviation 37.487	67.000 nanograms per milliliter (ng/mL) Standard Deviation 66.731	42.940 nanograms per milliliter (ng/mL) Standard Deviation 18.447	24.367 nanograms per milliliter (ng/mL) Standard Deviation 16.404	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 1 hour post-dose: Day 28 Cycle 1	24.473 nanograms per milliliter (ng/mL) Standard Deviation 29.361	110.300 nanograms per milliliter (ng/mL) Standard Deviation 46.245	56.150 nanograms per milliliter (ng/mL) Standard Deviation 51.474	113.333 nanograms per milliliter (ng/mL) Standard Deviation 85.096	101.740 nanograms per milliliter (ng/mL) Standard Deviation 64.018	140.533 nanograms per milliliter (ng/mL) Standard Deviation 137.107	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 2 hours post-dose: Day 28 Cycle 1	21.803 nanograms per milliliter (ng/mL) Standard Deviation 15.134	61.550 nanograms per milliliter (ng/mL) Standard Deviation 14.779	108.175 nanograms per milliliter (ng/mL) Standard Deviation 39.401	126.500 nanograms per milliliter (ng/mL) Standard Deviation 78.665	149.460 nanograms per milliliter (ng/mL) Standard Deviation 74.134	219.250 nanograms per milliliter (ng/mL) Standard Deviation 186.323	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 4 hours post-dose: Day 28 Cycle 1	25.767 nanograms per milliliter (ng/mL) Standard Deviation 2.050	55.750 nanograms per milliliter (ng/mL) Standard Deviation 22.698	111.950 nanograms per milliliter (ng/mL) Standard Deviation 33.596	115.000 nanograms per milliliter (ng/mL) Standard Deviation 22.068	145.720 nanograms per milliliter (ng/mL) Standard Deviation 57.106	133.333 nanograms per milliliter (ng/mL) Standard Deviation 17.559	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 8 hours post-dose: Day 28 Cycle 1	16.700 nanograms per milliliter (ng/mL) Standard Deviation 3.341	32.700 nanograms per milliliter (ng/mL) Standard Deviation 4.667	62.750 nanograms per milliliter (ng/mL) Standard Deviation 21.418	66.867 nanograms per milliliter (ng/mL) Standard Deviation 14.230	97.560 nanograms per milliliter (ng/mL) Standard Deviation 29.737	81.533 nanograms per milliliter (ng/mL) Standard Deviation 12.052	—	—	—	—	—
Dose Escalation Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 2	8.593 nanograms per milliliter (ng/mL) Standard Deviation 4.588	17.500 nanograms per milliliter (ng/mL) Standard Deviation 7.292	17.880 nanograms per milliliter (ng/mL) Standard Deviation 7.265	19.200 nanograms per milliliter (ng/mL) Standard Deviation 2.121	30.400 nanograms per milliliter (ng/mL) Standard Deviation 13.557	16.833 nanograms per milliliter (ng/mL) Standard Deviation 5.341	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 2, 15, 16, 28 of Cycle 1 and Day 1 of Cycle 2 (each cycle is 28 days)

Population: The PKAS included all patients who received at least 1 dose of HMPL-689 and had at least 1 PK sample obtained and analyzed. Only patients with data collected at specified timepoints are reported.

Blood samples were collected to determine Ctrough of HMPL-689. The PK parameters were determined by non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation Stage: Plasma Trough Concentration (Ctrough) of HMPL-689 Day 2: Cycle 1	4.490 ng/mL Standard Deviation 1.360	8.290 ng/mL Standard Deviation 4.398	12.442 ng/mL Standard Deviation 5.112	8.887 ng/mL Standard Deviation 4.148	20.017 ng/mL Standard Deviation 8.614	13.433 ng/mL Standard Deviation 1.501	—	—	—	—	—
Dose Escalation Stage: Plasma Trough Concentration (Ctrough) of HMPL-689 Day 15: Cycle 1	4.580 ng/mL Standard Deviation 0.521	35.613 ng/mL Standard Deviation 39.872	16.600 ng/mL Standard Deviation 6.678	16.650 ng/mL Standard Deviation 4.031	31.160 ng/mL Standard Deviation 15.418	22.900 ng/mL Standard Deviation 11.077	—	—	—	—	—
Dose Escalation Stage: Plasma Trough Concentration (Ctrough) of HMPL-689 Day 16: Cycle 1	5.567 ng/mL Standard Deviation 0.958	11.050 ng/mL Standard Deviation 5.162	17.825 ng/mL Standard Deviation 4.234	—	31.320 ng/mL Standard Deviation 13.989	20.267 ng/mL Standard Deviation 9.393	—	—	—	—	—
Dose Escalation Stage: Plasma Trough Concentration (Ctrough) of HMPL-689 Day 28: Cycle 1	5.837 ng/mL Standard Deviation 1.257	10.885 ng/mL Standard Deviation 1.860	19.575 ng/mL Standard Deviation 9.215	25.133 ng/mL Standard Deviation 7.251	32.380 ng/mL Standard Deviation 17.181	21.200 ng/mL Standard Deviation 10.121	—	—	—	—	—
Dose Escalation Stage: Plasma Trough Concentration (Ctrough) of HMPL-689 Day 1: Cycle 2	6.140 ng/mL Standard Deviation 2.447	17.500 ng/mL Standard Deviation 7.292	17.880 ng/mL Standard Deviation 7.265	19.200 ng/mL Standard Deviation 2.121	30.400 ng/mL Standard Deviation 13.557	16.833 ng/mL Standard Deviation 5.341	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose on Day 1 of Cycles 1, 2, 3, 5, 7, 9, 11, 13 and on Day 15 of Cycle 1; 0 hour on Day 1 of Cycle 1; 1, 2, 3, 4 hours post-dose on Days 1 and 15 of Cycle 1 (each cycle is 28 days)

Blood samples were collected to determine plasma concentration of HMPL-689. The PK parameters were determined by non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=13 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=6 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=5 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 1	0.000 ng/mL Standard Deviation 0.000	1.685 ng/mL Standard Deviation 6.074	0.000 ng/mL Standard Deviation 0.000	0.000 ng/mL Standard Deviation 0.000	0.000 ng/mL Standard Deviation 0.000	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 0 hour post-dose: Day 1 Cycle 1	—	48.400 ng/mL Standard Deviation 61.060	—	—	NA ng/mL Standard Deviation NA NA indicates that mean and standard deviation (SD) were not estimable for n\<3, as pre-specified in the statistical analysis plan (SAP).	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 1 hour post-dose: Day 1 Cycle 1	54.743 ng/mL Standard Deviation 85.161	108.857 ng/mL Standard Deviation 74.766	145.600 ng/mL Standard Deviation 131.539	86.950 ng/mL Standard Deviation 93.589	75.750 ng/mL Standard Deviation 33.441	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 2 hours post-dose: Day 1 Cycle 1	104.233 ng/mL Standard Deviation 117.306	150.523 ng/mL Standard Deviation 51.261	171.000 ng/mL Standard Deviation 71.632	136.333 ng/mL Standard Deviation 114.031	132.460 ng/mL Standard Deviation 27.338	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 3 hours post-dose: Day 1 Cycle 1	101.967 ng/mL Standard Deviation 70.324	130.742 ng/mL Standard Deviation 54.780	131.600 ng/mL Standard Deviation 33.368	98.267 ng/mL Standard Deviation 70.926	116.667 ng/mL Standard Deviation 11.930	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 4 hours post-dose: Day 1 Cycle 1	111.833 ng/mL Standard Deviation 22.661	117.708 ng/mL Standard Deviation 62.408	108.833 ng/mL Standard Deviation 30.521	72.933 ng/mL Standard Deviation 37.302	119.720 ng/mL Standard Deviation 36.898	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 15 Cycle 1	22.933 ng/mL Standard Deviation 8.804	37.056 ng/mL Standard Deviation 22.923	31.363 ng/mL Standard Deviation 25.923	16.667 ng/mL Standard Deviation 16.220	115.880 ng/mL Standard Deviation 147.709	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 1 hour post-dose: Day 15 Cycle 1	142.967 ng/mL Standard Deviation 119.865	146.358 ng/mL Standard Deviation 92.001	125.917 ng/mL Standard Deviation 52.229	95.467 ng/mL Standard Deviation 66.718	180.800 ng/mL Standard Deviation 87.697	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 2 hours post-dose: Day 15 Cycle 1	233.667 ng/mL Standard Deviation 2.082	193.417 ng/mL Standard Deviation 92.573	167.433 ng/mL Standard Deviation 71.148	128.000 ng/mL Standard Deviation 88.705	190.400 ng/mL Standard Deviation 53.003	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 3 hours post-dose: Day 15 Cycle 1	179.000 ng/mL Standard Deviation 30.447	166.550 ng/mL Standard Deviation 65.746	140.867 ng/mL Standard Deviation 56.317	95.333 ng/mL Standard Deviation 38.783	165.000 ng/mL Standard Deviation 75.024	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 4 hours post-dose: Day 15 Cycle 1	140.667 ng/mL Standard Deviation 48.003	148.333 ng/mL Standard Deviation 44.252	123.483 ng/mL Standard Deviation 48.346	85.167 ng/mL Standard Deviation 35.335	153.520 ng/mL Standard Deviation 46.202	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 2	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	61.493 ng/mL Standard Deviation 69.318	30.666 ng/mL Standard Deviation 23.182	15.237 ng/mL Standard Deviation 5.614	37.060 ng/mL Standard Deviation 25.195	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 3	32.633 ng/mL Standard Deviation 15.667	39.367 ng/mL Standard Deviation 36.625	41.815 ng/mL Standard Deviation 34.757	12.890 ng/mL Standard Deviation 8.707	43.800 ng/mL Standard Deviation 13.444	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 5	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	82.100 ng/mL Standard Deviation 55.917	40.412 ng/mL Standard Deviation 40.658	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	25.167 ng/mL Standard Deviation 25.877	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 7	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	23.983 ng/mL Standard Deviation 35.772	19.733 ng/mL Standard Deviation 11.057	75.967 ng/mL Standard Deviation 54.444	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 9	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	49.400 ng/mL Standard Deviation 46.088	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	18.533 ng/mL Standard Deviation 10.883	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 11	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	—	—	—	—	—	—	—
Dose Expansion Stage: Plasma Concentration of HMPL-689 Pre-dose: Day 1 Cycle 13	—	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	NA ng/mL Standard Deviation NA NA indicates that mean and SD were not estimable for n\<3, as pre-specified in the SAP.	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 of Cycles 1, 2, 3, 5, 7, 9, 11, 13 and on Day 15 of Cycle 1 (each cycle is 28 days)

Blood samples were collected to determine Ctrough of HMPL-689. The PK parameters were determined by non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=12 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=6 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=4 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 1: Cycle 1	—	21.900 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	—	—	—	—	—	—	—	—	—
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 15: Cycle 1	22.933 ng/mL Standard Deviation 8.804	37.056 ng/mL Standard Deviation 22.923	31.363 ng/mL Standard Deviation 25.923	16.667 ng/mL Standard Deviation 16.220	132.125 ng/mL Standard Deviation 165.321	—	—	—	—	—	—
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 1: Cycle 2	24.550 ng/mL Standard Deviation 2.758	41.013 ng/mL Standard Deviation 36.989	30.666 ng/mL Standard Deviation 23.182	15.237 ng/mL Standard Deviation 5.614	46.325 ng/mL Standard Deviation 16.555	—	—	—	—	—	—
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 1: Cycle 3	23.750 ng/mL Standard Deviation 4.172	46.214 ng/mL Standard Deviation 38.254	33.587 ng/mL Standard Deviation 37.495	14.390 ng/mL Standard Deviation 11.752	43.800 ng/mL Standard Deviation 13.444	—	—	—	—	—	—
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 1: Cycle 5	36.450 ng/mL Standard Deviation 15.627	63.625 ng/mL Standard Deviation 43.513	49.225 ng/mL Standard Deviation 41.065	18.150 ng/mL Standard Deviation 11.102	25.167 ng/mL Standard Deviation 25.877	—	—	—	—	—	—
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 1: Cycle 7	34.050 ng/mL Standard Deviation 6.293	27.950 ng/mL Standard Deviation 9.829	32.550 ng/mL Standard Deviation 46.033	22.850 ng/mL Standard Deviation 13.647	75.967 ng/mL Standard Deviation 54.444	—	—	—	—	—	—
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 1: Cycle 9	37.400 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	59.050 ng/mL Standard Deviation 60.740	61.600 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	18.533 ng/mL Standard Deviation 10.883	28.950 ng/mL Standard Deviation 4.596	—	—	—	—	—	—
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 1: Cycle 11	28.100 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	24.100 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	65.200 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	35.050 ng/mL Standard Deviation 30.193	—	—	—	—	—	—	—
Dose Expansion Stage: Plasma Trough Concentration of HMPL-689 Day 1: Cycle 13	—	29.600 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	18.800 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	17.300 ng/mL Standard Deviation NA NA indicates that SD could not be determined when only 1 patient was analyzed.	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 2 and 4 hours on Baseline (Day 1) of Cycle 1; 0, 2 and 4 hours on Day 15 of Cycle 1 (dose escalation phase); 1, 2, 3 and 4 hours on Baseline (Day 1) of Cycle 1; 0, 1, 2, 3, and 4 hours on Day 15 of Cycle 1 (dose expansion phase) (each cycle is 28 days)

Population: The FAS included all patients who received at least 1 dose of HMPL-689. As pre-specified in the protocol, the results are presented by dose level and combined data for dose expansion stage is presented for all patients evaluable for this endpoint who received HMPL-689 at RP2D (30 mg QD) in dose expansion stage. Only patients with data collected at specified timepoints are reported.

12-lead electrocardiogram was performed to evaluate the effect of HMPL-689 on cardiac repolarization by detecting the changes in QTcF intervals. Baseline was defined as the last assessment performed prior to or on first non-zero dose date with time point marked as "pre-dose".

Outcome measures

Outcome measures
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 Participants Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 Participants Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 Participants Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 Participants Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 Participants Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 Participants Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=30 Participants Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 1 hour: Day 1 Cycle 1	—	—	—	—	—	—	-5.14 millisecond (msec) Standard Deviation 10.6	—	—	—	—
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 2 hours: Day 1 Cycle 1	-6.89 millisecond (msec) Standard Deviation 5.68	17.3 millisecond (msec) Standard Deviation 0.471	-10.4 millisecond (msec) Standard Deviation 7.51	-11.5 millisecond (msec) Standard Deviation 9.19	-13.3 millisecond (msec) Standard Deviation 13.5	-18.5 millisecond (msec) Standard Deviation 2.59	-1.43 millisecond (msec) Standard Deviation 9.80	—	—	—	—
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 3 hours: Day 1 Cycle 1	—	—	—	—	—	—	-2.21 millisecond (msec) Standard Deviation 9.98	—	—	—	—
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 4 hours: Day 1 Cycle 1	-8.33 millisecond (msec) Standard Deviation 7.00	9.67 millisecond (msec) Standard Deviation 5.66	2.27 millisecond (msec) Standard Deviation 13.6	6.11 millisecond (msec) Standard Deviation 5.82	-9.33 millisecond (msec) Standard Deviation 17.9	-10.7 millisecond (msec) Standard Deviation 8.82	-2.46 millisecond (msec) Standard Deviation 10.2	—	—	—	—
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 0 hour: Day 15 Cycle 1	-11.3 millisecond (msec) Standard Deviation 21.7	-0.333 millisecond (msec) Standard Deviation 8.49	-2.17 millisecond (msec) Standard Deviation 8.72	-9.83 millisecond (msec) Standard Deviation 2.59	-4.33 millisecond (msec) Standard Deviation 13.6	-3.50 millisecond (msec) Standard Deviation 4.01	0.231 millisecond (msec) Standard Deviation 11.9	—	—	—	—
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 1 hour: Day 15 Cycle 1	—	—	—	—	—	—	2.11 millisecond (msec) Standard Deviation 11.2	—	—	—	—
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 2 hours: Day 15 Cycle 1	-10.6 millisecond (msec) Standard Deviation 7.70	1.50 millisecond (msec) Standard Deviation 3.06	-0.583 millisecond (msec) Standard Deviation 5.65	-7.22 millisecond (msec) Standard Deviation 7.83	-10.0 millisecond (msec) Standard Deviation 16.4	-14.8 millisecond (msec) Standard Deviation 10.6	-0.524 millisecond (msec) Standard Deviation 9.83	—	—	—	—
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 3 hours: Day 15 Cycle 1	—	—	—	—	—	—	0.614 millisecond (msec) Standard Deviation 8.47	—	—	—	—
Dose Escalation and Dose Expansion Stages: Change From Baseline in Corrected QT Interval (QTc) Using Fridericia Formula (QTcF) 4 hours: Day 15 Cycle 1	-13.1 millisecond (msec) Standard Deviation 12.1	6.67 millisecond (msec) Standard Deviation 12.7	-2.17 millisecond (msec) Standard Deviation 7.33	-9.11 millisecond (msec) Standard Deviation 10.9	-4.27 millisecond (msec) Standard Deviation 18.8	-11.0 millisecond (msec) Standard Deviation 11.7	-0.964 millisecond (msec) Standard Deviation 11.2	—	—	—	—

Deaths: 1 deaths

Dose Expansion Stage: MCL

Serious events: 3 serious events

Other events: 5 other events

Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 participants at risk Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 participants at risk Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 participants at risk Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 participants at risk Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 participants at risk Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 participants at risk Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=3 participants at risk Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL n=13 participants at risk Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL n=6 participants at risk Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM n=3 participants at risk Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL n=5 participants at risk Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Infections and infestations Pyelonephritis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Pneumonia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations COVID-19	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	15.4% 2/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Clostridium difficile colitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Cytomegalovirus infection reactivation	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations COVID-19 pneumonia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Pneumocystis jirovecii pneumonia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Urinary tract infection	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Colitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Colitis ulcerative	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Diarrhoea	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Asthenia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Disease progression	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Injury, poisoning and procedural complications Multiple fractures	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Epilepsy	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Psychiatric disorders Psychotic disorder	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Cutaneous vasculitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Vascular disorders Hypotension	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Failure to thrive	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Renal and urinary disorders Renal failure	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.

Other adverse events

Other adverse events
Measure	Dose Escalation Stage: HMPL-689 5 mg QD n=3 participants at risk Patients received HMPL-689 5 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 10 mg QD n=3 participants at risk Patients received HMPL-689 10 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 15 mg QD n=5 participants at risk Patients received HMPL-689 15 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 20 mg QD n=3 participants at risk Patients received HMPL-689 20 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 25 mg QD n=6 participants at risk Patients received HMPL-689 25 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Escalation Stage: HMPL-689 30 mg QD n=3 participants at risk Patients received HMPL-689 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: CLL/SLL n=3 participants at risk Patients with CLL/SLL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: FL n=13 participants at risk Patients with FL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MZL n=6 participants at risk Patient with MZL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: LPL/WM n=3 participants at risk Patients with LPL/WM received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.	Dose Expansion Stage: MCL n=5 participants at risk Patients with MCL received HMPL-689 at RP2D, that is, 30 mg QD orally for continuous 28-day treatment cycles until PD, death, intolerable toxicity, investigator's assessment of no benefit from the study treatment, withdrawal from the study, or the end of study, whichever occurred first.
Infections and infestations Diarrhoea infectious	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Balance disorder	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Burning sensation	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Subcutaneous abscess	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Diarrhoea	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	60.0% 3/5 • Number of events 10 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 2/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	38.5% 5/13 • Number of events 6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 2/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Haemorrhoids	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Nausea	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	66.7% 2/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	30.8% 4/13 • Number of events 5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Vomiting	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	15.4% 2/13 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Constipation	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Dry mouth	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Haematemesis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Stomatitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	15.4% 2/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 2/6 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Swollen tongue	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Abdominal tenderness	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Anal rash	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Colitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Dyspepsia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Flatulence	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Lip swelling	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Melaena	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Odynophagia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Oral disorder	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Gastrointestinal disorders Saliva altered	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations COVID-19	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	30.8% 4/13 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Upper respiratory tract infection	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 2/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Urinary tract infection	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 7 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Bronchitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	15.4% 2/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Gastroenteritis viral	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Lyme disease	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Onychomycosis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Pneumonia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Respiratory tract infection	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Escherichia infection	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Escherichia urinary tract infection	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Genital herpes simplex	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Gingivitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Pharyngitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Rash pustular	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Infections and infestations Tinea infection	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Cutaneous vasculitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 2/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Dermatitis acneiform	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Dermatitis allergic	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Onychomadesis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Photosensitivity reaction	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Skin burning sensation	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Skin hypopigmentation	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Blood and lymphatic system disorders Anaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	66.7% 2/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	38.5% 5/13 • Number of events 6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Blood and lymphatic system disorders Eosinophilia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Blood and lymphatic system disorders Neutrophilia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Alanine aminotransferase increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Blood alkaline phosphatase increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	15.4% 2/13 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Aspartate aminotransferase increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	15.4% 2/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Blood creatinine increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	15.4% 2/13 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Blood creatine phosphokinase increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Electrocardiogram QT prolonged	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Platelet count decreased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations White blood cell count decreased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations White blood cell count increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Lipase increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 2/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Blood bilirubin increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Blood lactate dehydrogenase increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Activated partial thromboplastin time prolonged	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Amylase increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Blood cholesterol increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations CD4 lymphocytes decreased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations International normalised ratio increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Liver function test increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Lymphocyte count decreased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Neutrophil count decreased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Investigations Transaminases increased	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Arthralgia	66.7% 2/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	30.8% 4/13 • Number of events 5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Bone pain	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Pain in extremity	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Musculoskeletal and connective tissue disorders Spinal pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Increased upper airway secretion	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Respiratory tract inflammation	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Bronchostenosis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Laryngeal haemorrhage	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Lung disorder	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Headache	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Disturbance in attention	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Dizziness	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	15.4% 2/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Hypoaesthesia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Memory impairment	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Dysgeusia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Paraesthesia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Presyncope	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Nervous system disorders Syncope	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Fatigue	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	30.8% 4/13 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	40.0% 2/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Pyrexia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	66.7% 2/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 2/6 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Asthenia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Oedema peripheral	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Vaccination site pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders General physical health deterioration	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Chills	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Facial pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Influenza like illness	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Malaise	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Mass	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Non-cardiac chest pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
General disorders Peripheral swelling	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Dyslipidaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	23.1% 3/13 • Number of events 5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hypermagnesaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Vascular disorders Hypertension	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 2/6 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 2 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Vascular disorders Flushing	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Vascular disorders Hypotension	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Vascular disorders Lymphoedema	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Vascular disorders Phlebitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Injury, poisoning and procedural complications Fall	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Cardiac disorders Angina pectoris	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Cardiac disorders Bradycardia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Cardiac disorders Coronary artery disease	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Cardiac disorders Extrasystoles	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Cardiac disorders Tachycardia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Eye disorders Periorbital oedema	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Eye disorders Retinopathy	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Eye disorders Dry eye	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Eye disorders Erythema of eyelid	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Eye disorders Eye pruritus	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Eye disorders Vision blurred	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Immune system disorders Jarisch-Herxheimer reaction	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Immune system disorders Seasonal allergy	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Ear and labyrinth disorders Vertigo	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 4 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Ear and labyrinth disorders Middle ear inflammation	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Psychiatric disorders Insomnia	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Psychiatric disorders Anxiety	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Renal and urinary disorders Chronic kidney disease	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Renal and urinary disorders Dysuria	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	20.0% 1/5 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Renal and urinary disorders Leukocyturia	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	33.3% 1/3 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Renal and urinary disorders Micturition urgency	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Renal and urinary disorders Urinary incontinence	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal adenoma	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	7.7% 1/13 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.
Reproductive system and breast disorders Prostatitis	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/6 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/13 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	16.7% 1/6 • Number of events 1 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/3 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.	0.00% 0/5 • AEs and SAEs were collected from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months for dose escalation stage and 27 months for dose expansion stage. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1) up to 58 months. Analysis was performed on the FAS.

Additional Information

Chao Pan

HUTCHMED Limited

Phone: (+86)15215192478

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place